Last reviewed · How we verify

NCT03415815

An Observational Study to Evaluate Lymph Metastases and Prognoses of the Patients With Esophageal Cancer

Status unknown Last updated 30 January 2018
What this trial tests

trial testing Surgeries in Esophageal Cancer in 3,673 participants. Status unknown.

Timeline
12 December 2017
Primary endpoint
30 April 2018
30 April 2018

Quick facts

Lead sponsorHenan Cancer Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment3,673
Start date12 December 2017
Primary completion30 April 2018
Estimated completion30 April 2018
Sites10 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Henan Cancer Hospital

Who can join

18 and older, any sex, with Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The real-world observational study was designed to explore lymph metastases and prognoses of the Chinese patients with thoracic T1-T3 esophageal cancer

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Surgeries

Trials testing the same drug.

Other recruiting trials for Esophageal Cancer

Currently open trials in the same condition.

Other Henan Cancer Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03415815.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing